S&P 500   3,958.53 (-0.13%)
DOW   33,679.56 (-0.30%)
QQQ   284.26 (+0.14%)
AAPL   144.21 (+1.09%)
MSFT   247.04 (-0.15%)
META   116.85 (+1.32%)
GOOGL   93.64 (-0.07%)
AMZN   89.56 (-0.87%)
TSLA   180.51 (+4.08%)
NVDA   173.05 (+0.79%)
NIO   12.85 (-4.18%)
BABA   92.45 (-1.83%)
AMD   69.67 (-1.14%)
T   19.18 (+0.31%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   94.14 (+1.72%)
AMC   5.84 (-3.79%)
PYPL   74.22 (+0.00%)
PFE   51.92 (+0.27%)
NFLX   325.07 (+4.77%)
S&P 500   3,958.53 (-0.13%)
DOW   33,679.56 (-0.30%)
QQQ   284.26 (+0.14%)
AAPL   144.21 (+1.09%)
MSFT   247.04 (-0.15%)
META   116.85 (+1.32%)
GOOGL   93.64 (-0.07%)
AMZN   89.56 (-0.87%)
TSLA   180.51 (+4.08%)
NVDA   173.05 (+0.79%)
NIO   12.85 (-4.18%)
BABA   92.45 (-1.83%)
AMD   69.67 (-1.14%)
T   19.18 (+0.31%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   94.14 (+1.72%)
AMC   5.84 (-3.79%)
PYPL   74.22 (+0.00%)
PFE   51.92 (+0.27%)
NFLX   325.07 (+4.77%)
S&P 500   3,958.53 (-0.13%)
DOW   33,679.56 (-0.30%)
QQQ   284.26 (+0.14%)
AAPL   144.21 (+1.09%)
MSFT   247.04 (-0.15%)
META   116.85 (+1.32%)
GOOGL   93.64 (-0.07%)
AMZN   89.56 (-0.87%)
TSLA   180.51 (+4.08%)
NVDA   173.05 (+0.79%)
NIO   12.85 (-4.18%)
BABA   92.45 (-1.83%)
AMD   69.67 (-1.14%)
T   19.18 (+0.31%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   94.14 (+1.72%)
AMC   5.84 (-3.79%)
PYPL   74.22 (+0.00%)
PFE   51.92 (+0.27%)
NFLX   325.07 (+4.77%)
S&P 500   3,958.53 (-0.13%)
DOW   33,679.56 (-0.30%)
QQQ   284.26 (+0.14%)
AAPL   144.21 (+1.09%)
MSFT   247.04 (-0.15%)
META   116.85 (+1.32%)
GOOGL   93.64 (-0.07%)
AMZN   89.56 (-0.87%)
TSLA   180.51 (+4.08%)
NVDA   173.05 (+0.79%)
NIO   12.85 (-4.18%)
BABA   92.45 (-1.83%)
AMD   69.67 (-1.14%)
T   19.18 (+0.31%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.22 (+0.76%)
GE   82.27 (-1.63%)
DIS   94.14 (+1.72%)
AMC   5.84 (-3.79%)
PYPL   74.22 (+0.00%)
PFE   51.92 (+0.27%)
NFLX   325.07 (+4.77%)
NASDAQ:ANAB

AnaptysBio - ANAB Stock Forecast, Price & News

$28.55
+0.34 (+1.21%)
(As of 12/9/2022 01:57 PM ET)
Add
Compare
Today's Range
$27.88
$28.67
50-Day Range
$25.51
$30.97
52-Week Range
$18.20
$37.40
Volume
2,175 shs
Average Volume
211,489 shs
Market Capitalization
$811.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.83

AnaptysBio MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
22.1% Upside
$34.83 Price Target
Short Interest
Bearish
21.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.08) to ($3.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars

Medical Sector

598th out of 1,022 stocks

Pharmaceutical Preparations Industry

279th out of 499 stocks

ANAB stock logo

About AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Stock News Headlines

See More Headlines
Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Company Calendar

Last Earnings
11/08/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/06/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANAB
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.83
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+22.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-57,800,000.00
Net Margins
-3,003.32%
Pretax Margin
-3,003.32%

Debt

Sales & Book Value

Annual Sales
$63.17 million
Book Value
$12.89 per share

Miscellaneous

Free Float
18,794,000
Market Cap
$811.68 million
Optionable
Optionable
Beta
-0.03

Key Executives

  • Mr. Daniel R. Faga (Age 42)
    Interim Pres & CEO and Director
    Comp: $3.91k
  • Mr. Eric J. LoumeauMr. Eric J. Loumeau (Age 59)
    COO & Gen. Counsel
    Comp: $639.88k
  • Mr. Hamza  Suria M.B.A.Mr. Hamza Suria M.B.A. (Age 46)
    M.Sc., Advisory
    Comp: $836.53k
  • Dr. Paul F. Lizzul FAAD (Age 47)
    M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer
    Comp: $683.17k
  • Mr. Dennis M. Mulroy (Age 67)
    Chief Financial Officer
  • Mr. Benjamin Stone
    Sr. VP of Corp. Devel.
  • Ms. Beth Mueller
    Sr. VP of HR
  • Dr. Martin Dahl Ph.D.
    Sr. VP of Research













ANAB Stock - Frequently Asked Questions

Should I buy or sell AnaptysBio stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ANAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View ANAB analyst ratings
or view top-rated stocks.

What is AnaptysBio's stock price forecast for 2023?

6 analysts have issued twelve-month price targets for AnaptysBio's stock. Their ANAB share price forecasts range from $28.00 to $44.00. On average, they anticipate the company's share price to reach $34.83 in the next twelve months. This suggests a possible upside of 23.5% from the stock's current price.
View analysts price targets for ANAB
or view top-rated stocks among Wall Street analysts.

How have ANAB shares performed in 2022?

AnaptysBio's stock was trading at $34.75 on January 1st, 2022. Since then, ANAB shares have decreased by 18.8% and is now trading at $28.21.
View the best growth stocks for 2022 here
.

When is AnaptysBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our ANAB earnings forecast
.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings results on Tuesday, November, 8th. The biotechnology company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.71. The biotechnology company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $17.36 million. AnaptysBio had a negative net margin of 3,003.32% and a negative trailing twelve-month return on equity of 42.04%.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by a number of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (8.89%), Federated Hermes Inc. (8.35%), BlackRock Inc. (6.22%), Vanguard Group Inc. (6.14%), State Street Corp (4.47%) and Dimensional Fund Advisors LP (3.13%). Insiders that own company stock include Ecor1 Capital, Llc, Eric J Loumeau and Hamza Suria.
View institutional ownership trends
.

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $28.21.

How much money does AnaptysBio make?

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $802.01 million and generates $63.17 million in revenue each year. The biotechnology company earns $-57,800,000.00 in net income (profit) each year or ($4.82) on an earnings per share basis.

How many employees does AnaptysBio have?

The company employs 102 workers across the globe.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com.

This page (NASDAQ:ANAB) was last updated on 12/9/2022 by MarketBeat.com Staff